Gencurix, Inc. is engaged in developing and manufacturing of cancer diagnostic test kits. Its products include GenesWell BCT, GenesWell ddEGFR Mutation Test, GenesWell CDx EGFR Mutation Test, and GenesWell ddEGFR Mutation Test. The company was founded on September 21, 2011 and is headquartered in Seoul, South Korea.

Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany.

Part of VolitionRX Ltd., Belgian Volition SPRL is a Belgian company located in Gosselies that provides diagnostics services for cancer patients. The firm was founded by Jacob Vincent Micallef. On October 11, 2010 Singapore Volition Pte Ltd., part of VolitionRX Ltd. since October 2011, acquired Belgian Volition SPRL from ValiRx Plc for $0.75 million.

Precogify offers B-GPS disease-causing gene prediction technology. They cooperate with the data in the early stage of the project to systematically screen tissue-specific disease-causing genes and directly verify and re-test in the queue.

Amadix develops and commercializes breakthrough discoveries in cancer diagnosis with a clear commercial rationale, addressing unmet medical needs in oncology. After analytical validation and demonstration of clinical validity and utility through international multicentre studies, the products will be commercialized worldwide. The most advanced product developed by Amadix is Colofast, an innovative non-invasive screening signature for colorectal cancer (CRC) and advanced adenoma diagnosis in blood designed to solve a significant health priority: the high mortality rate due to colon cancer worldwide (around half of the diagnosed patients). Amadix team consist of industry veterans with robust expertise in the Oncology Diagnostic area. They are a top level management team with international experience in cancer diagnostics, the pharmaceutical industry, the biotechnology sector and intellectual property. Amadix also has independent board members with international profiles and many years of experience in oncology and diagnostics, who advise the management team on strategy, commercialization and business development in Europe and the US.

Ammunition is a biotech company that creates technology for early cancer detection with a focus on endometrial, colorectal, cervical, and esophageal cancer. To help clinicians effectively detect, diagnose, and treat early cancer, the firm conducts research and develops early cancer detection technologies using epigenetics, nanomaterials, bioinformatics, big data technology, and artificial intelligence analysis.

Abbott Molecular is an emerging leader in molecular diagnostics and the analysis of DNA, RNA, and proteins at the molecular level. They are committed to exploring new clinical frontiers through the development and delivery of system and assay solutions that are designed to provide earlier disease diagnosis, selection of appropriate therapies and monitoring of disease recurrence. Their expanding portfolio brings multiples technologies that enable fast, accurate results. Their state of the art research and manufacturing facilities have hundreds of scientists who are dedicated to producing quality and reliable products. Over 350 products are available in the areas of infectious disease, oncology, genetics, and automation. Some of these products include: the m2000 system which has an extensive assay menu in infectious disease featuring Abbott RealTime technology with a broad range of assays, PathVysion HER-2 DNA Probe Kit for breast cancer, ALK Break Apart FISH Probe Kit, and UroVysion Bladder Cancer Kit are important applications of the FISH technology.

Zhenao Biotechnology Testing (Shenzhen) Co., Ltd., established on 2021-08-22, Business scope includes general business items:Inspection and testing service(Does not involve human stem cells,Genetic testing and special management measures for foreign business access);Research and development of bio-based materials technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Domestic trade agent.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license);software sales;software development;Software outsourcing service;Sales of Class I Medical Devices;Class I Medical Device Leasing.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license),The licensing program is:Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments);Class II Medical Device Leasing;Sales of Class II Medical Devices;Class III medical device business;Class III Medical Device Leasing.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Second Genome’s mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery. Second Genome has completed more than 400 microbiome studies, analyzing more than 75,000 samples, for internal R&D, as well as for external partners across government, academia, pharmaceutical, nutrition and industrial companies. The team leverages its microbiome analysis platform with its partners’ specific expertise to generate insightful findings that can accelerate research programs by elucidating the role of the microbiome in human health conditions, agriculture, animal health and other industries. The company has established a pipeline of therapeutic products for the treatment of inflammation and metabolic diseases.

Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.

Shanghai Biotree offers to test and consulting services for biotechnology. Customers who use the company's services can conduct various biotechnological studies and product quality tests. By utilizing its cutting-edge life sciences research, it also provides expert consulting services. In the area of large life sciences, they are dedicated to sampling testing, big data analysis, and technological product creation. They also pledge to be client-focused and offer expert services.

anghai Ruiyi Biotechnology Co., Ltd. was established in Shanghai in 2014 and is a national high-tech enterprise. At present, it has established branches in Hangzhou, Qingdao and Guiyang. It is a professional genetic technology and health service company. The company has always been adhering to the corporate philosophy of "forge ahead" and is committed to providing customers with the highest quality products and services. Since its inception, Shanghai Ruiyi Biotechnology Co., Ltd. has quickly established cooperation with many well-known research institutes at home and abroad, and has attracted many elites from the fields of genomics, medicine and bioinformatics. Up to now, the company has obtained more than 40 software copyrights and a number of patents.

Commonwealth Scientific & Industrial Research Organisation provides scientific and industrial research services. It plays a role in collaboration within the Australian national innovation system and as an advisor to government, industry and the community. The company was founded in 1916 and is headquartered in Canberra, Australia.

GeneGenieDx develops bioinformatics and machine learning algorithms for the discovery of immune diagnostic biomarkers and immunotherapy targets. They provide biomarkers and translates them into better clinical diagnostic products.

National Research Council of Canada, provides research & development. It services include research programs and collaboration opportunities, technical and advisory services, licensing opportunities and industrial research assistance program. The company was founded by Graham W. Burton and is headquartered in Ottawa, ON.

John Wayne Cancer Institute is a private company headquartered in Santa Monica, CA, that operates cancer research institute.\nThe company says this about itself: Since 1981, the family of John Wayne has been committed to pioneering cancer research in memory of their father, who died of cancer. The courageous and dedicated researchers at the John Wayne Cancer Institute have made groundbreaking discoveries that have changed the way cancer is detected, diagnosed and treated around the world. Today the tradition of excellence continues as the Institute spearheads new research advances, while training the next generation of leaders in the fight against cancer through its renowned Surgical Oncology Fellowship Program. The Institute provides immediate hope to cancer patients everywhere.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.